CL2023003607A1 - Anticuerpos anti-ccr8 y usos de los mismos - Google Patents
Anticuerpos anti-ccr8 y usos de los mismosInfo
- Publication number
- CL2023003607A1 CL2023003607A1 CL2023003607A CL2023003607A CL2023003607A1 CL 2023003607 A1 CL2023003607 A1 CL 2023003607A1 CL 2023003607 A CL2023003607 A CL 2023003607A CL 2023003607 A CL2023003607 A CL 2023003607A CL 2023003607 A1 CL2023003607 A1 CL 2023003607A1
- Authority
- CL
- Chile
- Prior art keywords
- ccr8 antibodies
- ccr8
- antibodies
- antigen
- binding fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197271P | 2021-06-04 | 2021-06-04 | |
| US202163236551P | 2021-08-24 | 2021-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003607A1 true CL2023003607A1 (es) | 2024-06-07 |
Family
ID=82358418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003607A CL2023003607A1 (es) | 2021-06-04 | 2023-12-04 | Anticuerpos anti-ccr8 y usos de los mismos |
| CL2024003552A CL2024003552A1 (es) | 2021-06-04 | 2024-11-20 | Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024003552A CL2024003552A1 (es) | 2021-06-04 | 2024-11-20 | Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12258411B2 (enExample) |
| EP (1) | EP4347655A1 (enExample) |
| JP (1) | JP2024522360A (enExample) |
| KR (1) | KR20240017912A (enExample) |
| AU (1) | AU2022285741A1 (enExample) |
| BR (1) | BR112023025433A2 (enExample) |
| CA (1) | CA3222764A1 (enExample) |
| CL (2) | CL2023003607A1 (enExample) |
| CO (1) | CO2023018064A2 (enExample) |
| CR (1) | CR20230581A (enExample) |
| IL (1) | IL308808A (enExample) |
| JO (1) | JOP20230312A1 (enExample) |
| MX (1) | MX2023014458A (enExample) |
| PE (1) | PE20240363A1 (enExample) |
| TW (1) | TW202313684A (enExample) |
| UY (1) | UY39798A (enExample) |
| WO (1) | WO2022256563A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308808A (en) * | 2021-06-04 | 2024-01-01 | Amgen Inc | Antibodies against CCR8 and their uses |
| WO2024097741A1 (en) * | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
| AR131785A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinaciones de inhibidores de dgk (diacilglicerol quinasa) |
| WO2024248037A1 (ja) | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Ｃｃｒ８を抗原として認識する二重特異性抗体 |
| AU2024305430A1 (en) * | 2023-06-12 | 2026-01-22 | Nanjing Probio Biotech Co., Ltd. | Antibody binding to human ccr8 and the use thereof |
| AU2024354737A1 (en) | 2023-10-06 | 2026-04-16 | Amgen Inc. | Combination therapy for cancer treatment |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| JP2019122373A (ja) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗ｐｄ−１抗体及び治療方法 |
| CN110835371A (zh) | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| KR102940634B1 (ko) * | 2018-12-27 | 2026-03-17 | 시오노기세이야쿠가부시키가이샤 | 신규 항 ccr8 항체 |
| TWI906906B (zh) * | 2020-01-06 | 2025-12-01 | 美商法西尼克斯股份有限公司 | 抗ccr8抗體及其用途 |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| CN115768792A (zh) | 2020-03-23 | 2023-03-07 | 百时美施贵宝公司 | 抗ccr8抗体用于治疗癌症 |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| EP4173636A4 (en) | 2020-06-30 | 2024-08-28 | Shionogi & Co., Ltd | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| JP2023538897A (ja) | 2020-08-20 | 2023-09-12 | アムジエン・インコーポレーテツド | Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質 |
| CN117098561A (zh) | 2020-08-28 | 2023-11-21 | 和铂医药美国股份有限公司 | Ccr8抗体及其应用 |
| WO2022081718A1 (en) * | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CA3198647A1 (en) | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| EP4267621A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Murine cross-reactive human ccr8 binders |
| EP4267617A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Human ccr8 binders |
| US20240052044A1 (en) | 2020-12-24 | 2024-02-15 | Vib Vzw | Non-blocking human ccr8 binders |
| AU2022287014A1 (en) * | 2021-06-04 | 2023-12-07 | Amgen Inc. | T cell engager molecules and uses thereof |
| IL308808A (en) * | 2021-06-04 | 2024-01-01 | Amgen Inc | Antibodies against CCR8 and their uses |
-
2022
- 2022-06-02 IL IL308808A patent/IL308808A/en unknown
- 2022-06-02 US US17/831,398 patent/US12258411B2/en active Active
- 2022-06-02 EP EP22736093.0A patent/EP4347655A1/en active Pending
- 2022-06-02 WO PCT/US2022/032011 patent/WO2022256563A1/en not_active Ceased
- 2022-06-02 PE PE2023003211A patent/PE20240363A1/es unknown
- 2022-06-02 CA CA3222764A patent/CA3222764A1/en active Pending
- 2022-06-02 MX MX2023014458A patent/MX2023014458A/es unknown
- 2022-06-02 KR KR1020247000218A patent/KR20240017912A/ko active Pending
- 2022-06-02 UY UY0001039798A patent/UY39798A/es unknown
- 2022-06-02 JP JP2023574361A patent/JP2024522360A/ja active Pending
- 2022-06-02 CR CR20230581A patent/CR20230581A/es unknown
- 2022-06-02 TW TW111120681A patent/TW202313684A/zh unknown
- 2022-06-02 AU AU2022285741A patent/AU2022285741A1/en active Pending
- 2022-06-02 BR BR112023025433A patent/BR112023025433A2/pt unknown
-
2023
- 2023-11-29 JO JOJO/P/2023/0312A patent/JOP20230312A1/ar unknown
- 2023-12-04 CL CL2023003607A patent/CL2023003607A1/es unknown
- 2023-12-20 CO CONC2023/0018064A patent/CO2023018064A2/es unknown
-
2024
- 2024-11-20 CL CL2024003552A patent/CL2024003552A1/es unknown
-
2025
- 2025-01-28 US US19/039,566 patent/US20250171549A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024522360A (ja) | 2024-06-18 |
| KR20240017912A (ko) | 2024-02-08 |
| US12258411B2 (en) | 2025-03-25 |
| TW202313684A (zh) | 2023-04-01 |
| AU2022285741A1 (en) | 2023-12-14 |
| CO2023018064A2 (es) | 2024-01-15 |
| IL308808A (en) | 2024-01-01 |
| JOP20230312A1 (ar) | 2023-11-29 |
| US20250171549A1 (en) | 2025-05-29 |
| EP4347655A1 (en) | 2024-04-10 |
| MX2023014458A (es) | 2023-12-15 |
| BR112023025433A2 (pt) | 2024-02-27 |
| CR20230581A (es) | 2024-02-13 |
| WO2022256563A1 (en) | 2022-12-08 |
| PE20240363A1 (es) | 2024-03-04 |
| UY39798A (es) | 2022-12-30 |
| CA3222764A1 (en) | 2022-12-08 |
| CL2024003552A1 (es) | 2025-08-01 |
| US20220403037A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023018064A2 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| CL2019002310A1 (es) | Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797) | |
| MX374810B (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| CL2020003391A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| AR120883A1 (es) | Anticuerpos anti-fgfr2b | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| CO2022004797A2 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| AR120886A1 (es) | Anticuerpos anti-fgfr2b | |
| AR051942A1 (es) | Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos | |
| MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
| CO2025007355A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
| AR120884A1 (es) | Anticuerpos anti-fgfr2b | |
| MX2021008216A (es) | Anticuerpos anti-tigit. | |
| MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
| CO2024007674A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| CO2024013551A2 (es) | Nuevos anticuerpos anti-cd3 y usos de los mismos | |
| CO2023010689A2 (es) | Anticuerpos y usos de estos | |
| MX2024002407A (es) | Anticuerpos y conjugados sirp-alfa. | |
| CO2022014878A2 (es) | Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos | |
| CL2023003151A1 (es) | Anticuerpos anti-notch2 y métodos de uso |